方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| 风险调整的IV期研究× | 倾向得分匹配× | |
|---|---|---|
| 领域≠ | 流行病学 | 研究统计学 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 1990s–2000s (formalized with ICH E2E and EMA PASS guidelines) | 1983 |
| 提出者≠ | Regulatory and pharmacoepidemiology community (ICH, EMA, FDA frameworks) | Paul Rosenbaum and Donald Rubin |
| 类型≠ | Observational / quasi-experimental clinical study design | Method |
| 开创性文献≠ | Strom, B. L. (Ed.). (2005). Pharmacoepidemiology (4th ed.). John Wiley & Sons. ISBN: 978-0470863107 | Rosenbaum, P. R., & Rubin, D. B. (1983). The central role of the propensity score in observational studies for causal effects. Biometrika, 70(1), 41–55. DOI ↗ |
| 别名≠ | risk-adjusted post-marketing surveillance study, adjusted Phase IV trial, risk-stratified post-authorization study, PASS with risk adjustment | PSM, propensity score weighting, covariate balance |
| 相关 | 3 | 3 |
| 摘要≠ | A risk-adjusted Phase IV study is an observational or semi-experimental post-marketing study conducted after a drug or device has received regulatory approval. It uses statistical risk-adjustment techniques — such as propensity score matching, inverse probability weighting, or multivariable regression — to control for confounding by indication and baseline patient differences, thereby producing more credible safety, effectiveness, and utilization estimates than unadjusted real-world analyses. | Propensity score matching (PSM) is a method for reducing confounding bias in observational studies by balancing baseline characteristics between treatment groups, simulating randomization. Developed by Rosenbaum and Rubin (1983), it estimates the probability of receiving treatment given observed covariates, then matches or weights treated and control individuals with similar treatment probabilities. Widely used in medicine, epidemiology, and policy evaluation when randomized trials are infeasible or unethical, enabling estimation of treatment effects while controlling for selection bias. |
| ScholarGate数据集 ↗ |
|
|